Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) [Phase 1]

View source ↗

Summary

Phase 1 study of pembrolizumab (MK-3475) in participants with advanced non-small cell lung cancer completed; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2016-12-05